![]() |
市場調查報告書
商品編碼
1497676
癌症生物標記市場:按生物標記類型、癌症類型、技術、應用、最終用戶 - 2024-2030 年全球預測Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
癌症生物標記市場規模預計2023年為283.1億美元,2024年達到312.3億美元,預計2030年將達到577.5億美元,複合年成長率為10.71%。
癌症生物標記是可以在身體部位(例如血液或組織)中測量的物質或過程,可以幫助檢測體內是否有癌症。蛋白質、基因突變或其他分子顯示身體可能正在對抗癌症。癌症生物標記的使用不斷擴大,主要是由於技術進步提高了這些測試的準確性和速度。此外,人們對個人化醫療的認知不斷提高,透過為每位患者提供量身定做的治療來改善治療結果,從而擴大了癌症生物標記的應用。然而,測試中的假陽性或假陰性可能導致錯誤的治療決策,並可能對市場成長構成挑戰。然而,目前難以早期檢測的癌症類型(例如胰腺癌和卵巢癌)的生物標記的開拓有可能擴大市場擴張的範圍。此外,將生物標記與數位健康資訊系統結合有可能增強患者監測和持續治療協調。
主要市場統計 | |
---|---|
基準年[2023] | 283.1億美元 |
預測年份 [2024] | 312.3億美元 |
預測年份 [2030] | 577.5億美元 |
複合年成長率(%) | 10.71% |
區域洞察
在美洲,強大的醫療基礎設施以及對癌症篩檢和早期檢測的高度認知正在推動對癌症生物標記的需求。該地區,尤其是美國,是許多致力於開發新生物標記並將其商業化的大型生物技術和醫療保健公司的所在地。該市場從政府的支持措施和研發方面的大量投資中受益匪淺。由於西歐完善的醫療保健系統以及中東和非洲國家政府對癌症研究的支持不斷增加,EMEA(歐洲、中東和非洲)地區也是癌症生物標記的重要市場。由於醫療成本上升和癌症盛行率增加,亞太地區癌症生物標記領域呈現快速成長。中國、日本和印度等國家正大力投資醫療基礎設施和研究,推動成長。此外,這些經濟體的中產階級人口不斷成長,為實施先進的醫療保健解決方案(包括癌症生物標記)創造了巨大的機會。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在癌症生物標記市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對癌症生物標記市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在癌症生物標記市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[197 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.
Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 28.31 billion |
Estimated Year [2024] | USD 31.23 billion |
Forecast Year [2030] | USD 57.75 billion |
CAGR (%) | 10.71% |
Regional Insights
In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.
Market Insights
The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]
Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]
Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage